Cited by 102

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Why Are the Majority of Active Compounds in the CNS Domain Natural Products? A Critical Analysis

Bharate, Sonali S., Mignani, Serge, Vishwakarma, Ram A.·2018·Journal of Medicinal Chemistry

Abstract

Small-molecule natural products (NPs) have a long and successful track record of providing first-in-class drugs and pharmacophore (scaffolds) in all therapeutic areas, serving as a bridge between modern and traditional medicine. This trajectory has been remarkably successful in three key areas of modern therapeutics: cancers, infections, and CNS diseases. Beginning with the discovery of morphine 200 years ago, natural products have remained the primary source of new drugs/scaffolds for CNS diseases. In this perspective, we address the question: why are the majority of active compounds in the CNS domain natural products? Our analysis indicates that ∼84% approved drugs for CNS diseases are NPs or NP-inspired, and interestingly, 20 natural products provided more than 400 clinically approved CNS drugs. We have discussed unique physicochemical properties of NPs and NP-inspired vis-à-vis synthetic drugs, isoform selectivity, and evolutionary relationship, providing a rationale for increasing focus on natural product driven discovery for next-generation drugs for neurodegenerative diseases.

Overview

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.7b01922

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • TAC possesses a low molecular weight (<400 Da) and lipophilicity that favor drug uptake across all tissues, including the CNS.

    “TAC possesses a low molecular weight (<400 Da) and lipophilicity that favor drug uptake across all tissues, including the CNS.45”

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 220

  1. 10.1038/embor.2008.160 · DOI
  2. 10.1038/embor.2009.12 · DOI
  3. 10.1038/nrd1657 · DOI
  4. 10.1038/nrd4510 · DOI
  5. 10.1021/jm300344v · DOI
  6. 10.1021/acs.jnatprod.5b01055 · DOI · Paper page
  7. 10.1038/nchem.2479 · DOI · Paper page
  8. 10.1039/C6CS00842A · DOI
  9. 10.1126/science.1168243 · DOI
  10. 10.1002/jps.3080180413 · DOI
  11. 10.1038/535S1a · DOI
  12. 10.1021/cn500051h · DOI
  13. 10.1021/ja01588a033 · DOI
  14. 10.1039/CT9232300980 · DOI
  15. Naranjo C., 1967, Psychopharmacol. Bull., 4, 16
  16. 10.1039/CT9191500933 · DOI
  17. 10.1039/JR9270000001 · DOI
  18. 10.1039/an876010148b · DOI
  19. 10.1021/ja02228a011 · DOI
  20. 10.1007/BF02290345 · DOI
  21. 10.1039/ct9201701157 · DOI
  22. 10.1016/0165-0173(92)90012-B · DOI
  23. Willis R. C., 2002, Today’s Chemist at Work, 41
  24. 10.1002/cber.19040370206 · DOI
  25. Posselt W., 1828, Magazin Pharm., 6, 138
  26. 10.1007/978-3-540-69248-5_2 · DOI
  27. 10.1002/cber.189102401242 · DOI
  28. 10.1021/ja01163a126 · DOI
  29. 10.1038/nchembio.160 · DOI
  30. 10.1002/jlac.18330050108 · DOI
  31. 10.1002/cber.19010340124 · DOI
  32. Christison R., 1855, Monthly J. Med. Sci. (London), 20, 193
  33. 10.1039/CT9252700247 · DOI
  34. 10.1007/s11845-009-0460-z · DOI
  35. Daniell W. F., 1846, Proc. Ethnolog. Soc. Edinurgh, 40, 313
  36. 10.1002/cber.18980310316 · DOI
  37. 10.1002/ardp.18551320208 · DOI
  38. 10.3109/15563657508988061 · DOI
  39. 10.1002/ardp.18601530202 · DOI
  40. 10.1001/archinte.1916.00080120077003 · DOI
  41. 10.1016/S0022-5347(17)69270-X · DOI
  42. 10.1002/jlac.18480660121 · DOI
  43. Dale H. H., 1914, J. Pharm. Exp. Ther., 6, 147, 10.1016/S0022-3565(25)08268-0 · DOI
  44. 10.1111/j.2042-7158.1958.tb10285.x · DOI
  45. 10.1139/v92-346 · DOI
  46. 10.1007/BF02160615 · DOI
  47. 10.4997/JRCPE.2009.416 · DOI
  48. Stoll A., 1920, Verhandl. Schweiz Naturf. Ges., 101, 190
  49. 10.1021/ed047p695 · DOI
  50. 10.1002/ptr.4940 · DOI
  51. 10.1001/jama.1930.02710370034010 · DOI
  52. 10.1016/j.tips.2014.11.006 · DOI
  53. 10.1002/cber.188702001142 · DOI
  54. 10.1007/BF01524590 · DOI
  55. 10.1038/scientificamericanmind1207-66 · DOI
  56. 10.1007/BF01825267 · DOI
  57. 10.1021/ar00087a006 · DOI
  58. 10.1007/s00415-010-5741-y · DOI
  59. 10.1126/science.127.3296.471 · DOI
  60. 10.1139/cjr31-097 · DOI
  61. 10.1002/hlca.19590420518 · DOI
  62. 10.1111/j.1755-5949.2008.00059.x · DOI · Paper page
  63. 10.1021/ja01858a058 · DOI
  64. 10.1002/hlca.19670500235 · DOI
  65. 10.1002/hlca.19430260326 · DOI
  66. 10.1002/ana.410130110 · DOI
  67. 10.1007/BF02174406 · DOI
  68. 10.1038/scientificamerican0973-116 · DOI
  69. 10.7326/0003-4819-37-6-1144 · DOI
  70. 10.1021/ja01590a079 · DOI
  71. Mashkovsky M. D., 1951, Farmakol. Toxicol., 14, 27
  72. 10.1021/ed100388x · DOI
  73. 10.1021/cr040415t · DOI
  74. 10.1002/dta.1795 · DOI
  75. 10.1111/j.1527-3458.2004.tb00022.x · DOI
  76. 10.1039/c1sc00455g · DOI
  77. 10.1038/aps.2012.128 · DOI
  78. 10.1016/S0091-3057(03)00111-4 · DOI
  79. 10.1038/535S18a · DOI
  80. 10.1124/pr.112.007138 · DOI
  81. 10.1021/jo01362a018 · DOI
  82. 10.1073/pnas.77.4.2288 · DOI
  83. 10.1126/science.6281892 · DOI
  84. 10.1021/np9600816 · DOI
  85. 10.1021/jm00081a001 · DOI
  86. 10.1002/(SICI)1098-2299(199809)45:1<10::AID-DDR2>3.0.CO;2-G · DOI
  87. 10.1111/j.1527-3458.2005.tb00045.x · DOI
  88. 10.1080/10826076.2016.1266500 · DOI
  89. 10.1021/ja01198a012 · DOI
  90. 10.1016/S0167-4838(97)00133-7 · DOI
  91. 10.1097/00007611-197512000-00007 · DOI
  92. 10.1016/0006-8993(74)90664-7 · DOI
  93. Leung A. Y., 1969, Lloydia, 32, 66
  94. 10.1038/nrd1086 · DOI
  95. 10.1001/jama.1930.02710370034010 · DOI
  96. 10.1016/0003-9861(54)90500-7 · DOI
  97. 10.1016/j.lfs.2013.07.023 · DOI
  98. 10.2147/CPAA.S42832 · DOI
  99. Razdan R. K., 1986, Pharmacol. Rev., 38, 75, 10.1016/S0031-6997(25)06863-2 · DOI
  100. 10.1002/dta.1529 · DOI
  101. 10.1159/000357427 · DOI
  102. 10.1021/jm00111a053 · DOI
  103. 10.1159/000026529 · DOI
  104. 10.2165/11536200-000000000-00000 · DOI
  105. Osiezagha K., 2013, Innov. Clin. Neurosci., 10, 26
  106. 10.1111/j.1747-0285.2011.01105.x · DOI
  107. Goldstein A., 1960, J. Pharmacol. Exp. Ther., 128, 1
  108. 10.7164/antibiotics.25.660 · DOI
  109. 10.7164/antibiotics.36.142 · DOI
  110. 10.1016/0028-3908(83)90200-9 · DOI
  111. Moore N. A., 1992, J. Pharmacol. Exp. Ther., 262, 545, 10.1016/S0022-3565(25)10792-1 · DOI
  112. 10.1007/BF01670325 · DOI
  113. Rasoanaivo P., 2012, Drug Discovery in Africa—Impacts of Genomics, Natural Products, Traditional Medicines, Insights into Medicinal Chemistry, and Technology Platforms in Pursuit of New Drugs, 265
  114. 10.1111/j.1600-0447.1966.tb08812.x · DOI
  115. 10.1002/med.2610110402 · DOI
  116. 10.1007/BF00587776 · DOI
  117. 10.1038/sj.bjp.0706473 · DOI
  118. 10.1159/000136803 · DOI
  119. 10.1016/S1734-1140(13)71059-4 · DOI
  120. 10.1038/sj.ijo.0803272 · DOI
  121. 10.1038/sj.bjp.0706443 · DOI
  122. 10.1159/000339271 · DOI
  123. 10.1016/S0166-2236(00)01763-X · DOI
  124. 10.1016/S1471-4892(01)00003-0 · DOI
  125. 10.1016/j.peptides.2011.12.005 · DOI
  126. 10.1016/j.neuron.2012.09.009 · DOI
  127. 10.1016/S0172-2190(03)00110-8 · DOI
  128. 10.3390/molecules21050559 · DOI
  129. 10.1016/S2215-0366(16)30025-6 · DOI
  130. 10.1016/0277-9536(86)90194-2 · DOI
  131. 10.18632/oncotarget.16801 · DOI
  132. 10.1002/(SICI)1099-1565(199809/10)9:5<232::AID-PCA412>3.0.CO;2-5 · DOI
  133. 10.1002/hup.1180 · DOI
  134. 10.1016/j.spen.2011.06.007 · DOI
  135. 10.1016/j.smrv.2007.03.002 · DOI
  136. 10.1078/0944-7113-00374 · DOI
  137. 10.1002/jps.2600601002 · DOI
  138. 10.1517/17425255.2014.870554 · DOI
  139. 10.1016/j.steroids.2013.06.007 · DOI
  140. 10.1053/seiz.1999.0378 · DOI
  141. 10.1016/0304-3940(96)13000-7 · DOI
  142. 10.1001/archinte.1996.00440080101012 · DOI
  143. 10.1016/j.jep.2004.02.023 · DOI
  144. 10.1016/j.fitote.2003.07.007 · DOI
  145. 10.1016/j.jep.2004.02.012 · DOI
  146. 10.1055/s-2006-960042 · DOI
  147. 10.1021/np060254j · DOI
  148. 10.1007/BF02859006 · DOI
  149. 10.1111/j.1750-3841.2007.00535.x · DOI
  150. 10.1002/hup.470090206 · DOI
  151. 10.1007/BF02859320 · DOI
  152. 10.1002/jsfa.1598 · DOI
  153. 10.1021/np060253r · DOI
  154. 10.1002/hup.306 · DOI · Paper page
  155. 10.1076/phbi.36.5.327.4657 · DOI
  156. 10.1002/ptr.1407 · DOI
  157. 10.1007/s10600-011-9857-9 · DOI
  158. 10.3109/13880207909067451 · DOI
  159. 10.1016/S1875-5364(14)60111-4 · DOI
  160. Lapik A. S., 1968, Farmakol. Toksikol., 31, 650
  161. 10.1002/jnr.10429 · DOI
  162. 10.1016/j.jep.2007.12.007 · DOI
  163. 10.1016/j.phymed.2005.03.003 · DOI
  164. 10.1016/j.jep.2013.10.053 · DOI
  165. 10.1007/BF02860772 · DOI
  166. 10.1007/BF02042841 · DOI
  167. 10.1089/jmf.2000.3.153 · DOI
  168. 10.1007/s004140050135 · DOI
  169. 10.1021/np100550t · DOI
  170. 10.2174/0929867023368773 · DOI
  171. 10.1016/j.bbagen.2013.02.008 · DOI
  172. 10.1038/nchembio.320 · DOI
  173. 10.1038/nrd4243 · DOI
  174. 10.1039/b715668p · DOI
  175. 10.1039/C3NP70063A · DOI
  176. 10.1021/ci0200467 · DOI
  177. Waser P. G., 1961, Pharmacol. Rev., 13, 465, 10.1016/S0031-6997(25)07052-8 · DOI
  178. 10.1002/anie.201608526 · DOI
  179. 10.1016/0006-8993(75)90234-6 · DOI · Paper page
  180. 10.2174/2212796810701010115 · DOI
  181. 10.1016/j.nbd.2009.07.028 · DOI
  182. 10.1016/S1537-1891(02)00201-X · DOI
  183. 10.1111/j.1476-5381.2011.01557.x · DOI
  184. 10.1007/s12031-002-0008-4 · DOI
  185. 10.1016/j.jmgm.2010.03.010 · DOI
  186. 10.1124/dmd.106.009746 · DOI
  187. 10.2165/00003088-200645070-00009 · DOI
  188. 10.1126/science.178.4064.984 · DOI
  189. 10.1097/00007691-199101000-00001 · DOI
  190. 10.4065/84.7.613 · DOI
  191. 10.1038/jcbfm.2012.126 · DOI · Paper page
  192. 10.1038/nrd2999 · DOI
  193. 10.3389/fnmol.2011.00032 · DOI
  194. 10.1055/s-2006-958058 · DOI
  195. 10.1371/journal.pone.0052323 · DOI
  196. 10.1007/s40265-017-0720-6 · DOI
  197. 10.2165/00126839-200304050-00005 · DOI
  198. 10.1021/jm5006463 · DOI · Paper page
  199. 10.1038/nature23272 · DOI
  200. 10.1021/ja00730a036 · DOI

200 of 220 shown

Cited by

Sorted by citations

Metadata

Authors
Bharate, S. S., Mignani, S., & Vishwakarma, R. A.
Affiliations
  • Preformulation Laboratory, PK−PD Toxicology and Formulation Division, CSIR—Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India
  • UMR 860, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologique, Université Paris Descartes, PRES Sorbonne Paris Cité, CNRS, 45 rue des Saints Pères, 75006 Paris, France
  • Medicinal Chemistry Division, CSIR—Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India
Venue
Journal of Medicinal Chemistry
Published
2018-07-10
Volume
61
Issue
23
Pages
10345-10374
ISSN
  • 0022-2623
  • 1520-4804
Cited by
102
References
7
Language
en
Funders
Department of Biotechnology , Ministry of Science and Technology (GAP-2158)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review